A disappointing performance from one of these new drugs hitting the market right now could spell disaster for these stocks. Here's what to look for.
Mar 26, 2018 at 7:47AM
Get ready for a banner year of blockbuster drug launches.
According to a recent report from Clarivate Analytics, 12 new drugs are supposed to hit the market this year and reach $1 billion in annual sales by 2022. While entries from Gilead Sciences (NASDAQ:GILD), Alynlam Pharmaceuticals, Inc. (NASDAQ:ALNY), and GW Pharmaceuticals plc (NASDAQ:GWPH) aren't the largest, these three drugs are so important to the companies launching them that you won't want to stop watching them for a minute this year.